drugset / Trial / NCT00574483
Treatment of Advanced Renal Cell Carcinoma With Quinacrine
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The overall response to standard therapies and to the newer antiangiogenesis therapies is not curative, and treatment-associated toxicities may be severe. Therefore, continued evaluation of therapies, with different mechanisms of action, is needed for patients with metastatic RCC.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-01
- Completion
- 2008-01
Outcome
Outcome not reported
Stopped: “reevaluation of compound development”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quinacrine | Small molecule | 100 mg | — |